# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-23-285170
Filing Date
2023-11-29
Accepted
2023-11-29 16:02:58
Documents
5
Period of Report
2023-11-29

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | d614273d6k.htm | 6-K | 9027
2 | EX-99.1 | d614273dex991.htm | EX-99.1 | 58897
3 | GRAPHIC | g614273g1129100033338.jpg | GRAPHIC | 7252
4 | GRAPHIC | g614273g14p01.jpg | GRAPHIC | 371122
5 | GRAPHIC | g614273g15p01.jpg | GRAPHIC | 263738
| Complete submission text file | 0001193125-23-285170.txt |  | 953889

Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000 01161298780088
KAZIA THERAPEUTICS LTD (Filer) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 0630
Type: 6-K | Act: 34 | File No.: 000-29962 | Film No.: 231452142
SIC: 2834 Pharmaceutical Preparations